ClinicalTrials.gg
Active, not recruitingNCT06965413GYMINDAUpdated Sep 9, 2026

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

A Phase 2 interventional study of RO7204239 and RO7204239 Matching Placebo in Obesity, Overweight and Overweight With One Weight Related Comorbidity, sponsored by Hoffmann-La Roche. Active, not recruiting at 35 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.

Enrollment
12th of 21
285 · median 300
Started
2025
with 3 others
Phase 2
7 of 21
1 open now
Primary completion
2026-09
later than 0 of 11 live
Registered
9th of 21
by date

Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 12th largest by enrollment, is one of 4 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 0 of the 11 other live ones, and was the 9th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one of the 4 treatment arms; a 24-week treatment extension period, where participants will stop treatment with tirzepatide and a 24-week post-treatment follow-up (FU) period.

03

Conditions studied

  • Obesity
  • Overweight
  • Overweight With One Weight Related Comorbidity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 30.0 kilograms per square meter (kg/m²) (additional weight-related comorbidities are not required for inclusion)
  • BMI ≥ 27.0 kg/m² and \< 30.0 kg/m² with at least one weight-related comorbidity such as: hypertension, dyslipidemia, obstructive sleep apnea and any cardiovascular disease
  • History of at least one self-reported unsuccessful dietary or exercise effort to lose body weight
  • Weight stability: self-reported change in body weight less than 5 kilograms (kg) (11 pounds [lbs]) within 3 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Prior history or diagnosis of DM
  • Presence of non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy or diabetic macular edema
  • Have obesity induced by other endocrinologic disorders
  • Participation in unbalanced/extreme diets
  • Prior or planned surgical treatment for obesity
  • Endoscopic and/or device-based therapy for obesity or device removal within 6 months prior to screening
  • Have a known gastric emptying abnormality
  • Have any of the following cardiovascular conditions within 6 months prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or hospitalization due to congestive heart failure (CHF)
  • Have evidence of significant active, uncontrolled cardiovascular, , endocrine, renal, hepatic, dermatological, chronic respiratory or gastrointestinal disease, a neurological or psychiatric condition, or a history of any neuromuscular disorder or autoimmune/inflammatory disorders that may cause muscle wasting or medical condition capable of constituting a risk when taking the study medication or interfering with the interpretation of data, as judged by the investigator at screening
  • Have evidence of a significant, uncontrolled endocrine abnormality
  • Have a history of an active or untreated or are in remission from a clinically significant malignancy
  • Have evidence of a significant, active autoimmune abnormality
  • Have anemia
  • Have signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
285 participants (actual)

Study arms

  • Active comparator
    Placebo + Tirzepatide

    Participants will receive RO7204239 matching placebo via subcutaneous (SC) injection every 4 weeks (Q4W) for the core treatment period of 48 weeks and the treatment extension period of 24 weeks. Participants will also receive tirzepatide, as a background therapy, up-titrated according to the approved tirzepatide prescribing information, SC, every week (QW) during the core treatment period of 48 weeks.

    Drug: RO7204239 · Drug: RO7204239 Matching Placebo · Drug: Tirzepatide

  • Experimental
    RO7204239 low dose + Tirzepatide

    Participants will receive RO7204239, low dose, SC, Q4W for the core treatment period of 48 weeks. During the treatment extension period participants will receive placebo for the period of 24 weeks. Participants will also receive tirzepatide, as a background therapy, up-titrated according to the approved tirzepatide prescribing information, SC, QW during the core treatment period of 48 weeks.

    Drug: RO7204239 · Drug: Tirzepatide

  • Experimental
    RO7204239 medium dose + Tirzepatide

    Participants will receive RO7204239, medium dose, SC, Q4W for the core treatment period of 48 weeks. During the treatment extension period participants will receive placebo for the period of 24 weeks. Participants will also receive tirzepatide, as a background therapy, up-titrated according to the approved tirzepatide prescribing information, SC, QW during the core treatment period of 48 weeks.

    Drug: RO7204239 · Drug: Tirzepatide

  • Experimental
    RO7204239 high dose + Tirzepatide

    Participants will receive RO7204239, high dose, SC, Q4W along with tirzepatide, given as a background therapy, up-titrated according to the approved tirzepatide prescribing information, SC, QW during the core treatment period of 48 weeks. During the treatment extension period participants will be randomized to receive RO7204239 or matching placebo, SC, Q4W for 24 weeks.

    Drug: RO7204239 · Drug: Tirzepatide

Interventions

  • RO7204239 or matching placebo will be administered as per the schedule specified in the arms.

  • DrugRO7204239 Matching Placebo

    RO7204239 matching placebo will be administered as per the schedule specified in the arm.

  • Tirzepatide will be administered as per the schedule specified in the arms.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Absolute Change From Baseline in Body Weight

    Time frame: Baseline, Week 48

  2. Change From Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 48

  3. Change From Baseline in Waist-to-height Ratio

    Time frame: Baseline, Week 48

  4. Change From Baseline in Waist Circumference

    Time frame: Baseline, Week 48

  5. Change From Baseline in Total Body Fat Mass Measured by Dual-energy X-ray Absorptiometry (DXA)

    Time frame: Baseline, Week 48

  6. Change From Baseline in Total Lean Body Mass Measured by DXA

    Time frame: Baseline, Week 48

  7. Change From Baseline in Appendicular Lean Mass Measured by DXA at Week 48

    Time frame: Baseline, Week 48

  8. Change From Baseline in Muscle Volume Measured by Magnetic Resonance Imaging (MRI)

    Time frame: Baseline, Week 48

  9. Change From Baseline in Muscle Fat Infiltration Measured by MRI

    Time frame: Baseline, Week 48

  10. Change From Baseline in Glycated Hemoglobin (HbA1C) Levels

    Time frame: Baseline, Week 48

  11. Change From Baseline in Fasting Plasma Glucose Levels

    Time frame: Baseline, Week 48

  12. Change From Baseline in Fasting C-peptide and Fasting Insulin Levels

    Time frame: Baseline, Week 48

  13. Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

    Time frame: Baseline, Week 48

  14. Change From Baseline in Quantitative Insulin Sensitivity Check Index (QUICKI)

    Time frame: Baseline, Week 48

  15. Change From Baseline in Fasting Lipid Profile

    Fasting lipid profile includes total cholesterol, triglycerides, low-density lipoprotein (LDL), high-density lipoprotein (HDL), non-HDL cholesterol

    Time frame: Baseline, Week 48

  16. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 100 weeks

  17. Number of Participants With Local and Systemic Injection Reactions

    Time frame: Up to approximately 100 weeks

  18. Serum Concentrations of RO7204239

    Time frame: Up to approximately 96 weeks

  19. Steady-state Trough Concentration (Ctrough,ss) of RO7204239

    Time frame: Up to approximately 96 weeks

  20. Half-life (t1/2) of RO7204239

    Time frame: Up to approximately 96 weeks

  21. Steady-state Area Under the Concentration-time Curve Over One Dosing Interval (AUCtau,ss) of RO7204239

    Time frame: Up to approximately 96 weeks

  22. Steady-state Maximum Concentration (Cmax,ss) of RO7204239

    Time frame: Up to approximately 96 weeks

  23. Apparent Clearance (CL/F) of RO7204239

    Time frame: Up to approximately 96 weeks

  24. Apparent Volume of Distribution (Vd/F) of RO7204239

    Time frame: Up to approximately 96 weeks

  25. Number of Participants With Anti-drug Antibodies (ADAs) to RO7204239

    Time frame: Up to approximately 96 weeks

07

Study locations

35 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Sep 2026, 15 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 15 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2025
First posted
May 11, 2025
StartActual
May 5, 2025
Primary completionActual
Sep 3, 2026
CompletionEst.
Mar 31, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06965413
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 11, 2025
Start date
May 5, 2025
Primary completion
Sep 3, 2026
Completion
Mar 31, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emugrobart

Start the discussion